Key Points The Johns Hopkins Arthritis Center conducted a study to determine the presence of gum disease in patients who have Rheumatoid Arthritis (RA). Oral health exams were performed on patients who have RA and healthy volunteers for comparison. Data was collected from 100 RA patients and 40 healthy volunteers. 70% of the RA patients […]
I wanted to take this opportunity to provide you with an update on some of the activities and achievements in the Arthritis Center this year across each of our three mission areas: patient care, research, and education.
A recent study by the Johns Hopkins Arthritis Center reveals yoga holds positive results for arthritis sufferers in terms of both mind and body.
Apremilast (Otezla®) received FDA approval on March 21, 2014 for the treatment of adults with active psoriatic arthritis (PsA). It is the first oral medication in the U.S. with an approved indication for the treatment of PsA. The recommended dose is 30 mg BID
Certolizumab pegol (Cimzia®) gained FDA approval in September/October 2013 for two new indications, adults with active psoriatic arthritis (PsA) and adults with active ankylosing spondylitis (AS).